View the Published
Tutivia™ Validation Study
How to Order
Form
Who We Are
Leadership
Careers
Investors
Media
News
Events
Press Releases
Presentations
Investors
About Verici Dx
Regulatory News
Results, Events, & Presentations
Annual & Interim Reports
Financial Calendar
Shareholder Centre
Corporate Governance
FAQs
AIM Rule 26
Insights
Contact Us
Products
Tutivia™
Clarava™
Protega™
How to Order
Services
Technology
Background
RNA Signatures
Sequencing
Professionals
Clinical Data
Validation Study Results
Importance of a Risk Score
CLIA Lab
Patients
Patient Journey
Partners
AKF
ASN
AST
ASTS
KDIGO
NKF
Educational Center
Patient Journey
Publications
Video Resources
Downloadable Documents
Products
Tutivia™
Clarava™
Protega™
How to Order
Services
Technology
Background
RNA Signatures
Sequencing
Professionals
Clinical Data
Validation Study Results
Importance of a Risk Score
CLIA Lab
Patients
Patient Journey
Partners
AKF
ASN
AST
ASTS
KDIGO
NKF
Educational Center
Patient Journey
Publications
Video Resources
Downloadable Documents
How to Order
Form
Who We Are
Leadership
Careers
Investors
Media
News
Events
Press Releases
Presentations
Investors
About Verici Dx
Regulatory News
Results, Events, & Presentations
Annual & Interim Reports
Financial Calendar
Shareholder Centre
Corporate Governance
FAQs
AIM Rule 26
Insights
Contact Us
Press Releases
June 24, 2026
Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test
June 24, 2026
Keep Reading
June 17, 2026
Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026
June 17, 2026
Keep Reading
May 19, 2026
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
May 19, 2026
Keep Reading
close
chevron-down
bars
cross
menu
chevron-down
